Tempus AI (TEM) said Thursday that it has expanded its partnership with Takeda Pharmaceutical (TAK) to support Takeda's oncology research and development using real-world multimodal datasets and biological model systems.
Financial terms of the new agreement were not provided.
Tempus AI said Takeda will use Tempus AI' real-world data and AI tools for its cancer therapeutic pipeline.
The companies have also initiated a multi-phase project using patient-derived tumor organoids linked to Tempus' genetic sequencing, aiming to improve drug candidate prioritization and effectiveness predictions, Tempus said.
Shares of Tempus were up 1.7% in recent premarket activity, while Takeda was marginally down by 0.2%.
Price: 50.16, Change: +1.01, Percent Change: +2.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。